José F. Leis

Ibrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia

Tait D. Shanafelt, Xin V. Wang, Neil E. Kay et al. · New England Journal of Medicine · 2019 · 738 citations · Full text

Medicine, Immunology, Oncology +16

Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL

Wei Ding, Betsy LaPlant, Timothy G. Call et al. · Blood · 2017 · 412 citations · Full text

Medicine, Clinical Sciences, Oncology +6

Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial

Craig B. Reeder, Donna Reece, Vishal Kukreti et al. · Leukemia · 2009 · 371 citations · Full text

Medicine, Hematology, Oncology +15

Long-term outcomes for ibrutinib–rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial

Tait D. Shanafelt, Victoria Wang, Curtis A. Hanson et al. · Blood · 2022 · 237 citations · Full text

Medicine, Immunology, Pharmacotherapy +13

Hematopoietic Cell Transplantation After Nonmyeloablative Conditioning for Advanced Chronic Lymphocytic Leukemia

Mohamed L. Sorror, Michael B. Maris, Brenda M. Sandmaier et al. · Journal of Clinical Oncology · 2005 · 231 citations · Full text

Medicine, Hematology, Oncology +16